In its clinical trial against hyperlipidemia (NCT00701883), seladelpar reduced the assessed blood lipid parameters (triglyceride, total cholesterol, LDL-cholesterol, and free fatty acid levels), the alkaline phosphatase and γ-glutamyl transferase (GGT) activities, and the homeostatic model assessment–insulin resistance [46]. This evidence concerns the gene INS and hyperlipidemia.